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1. Introduction
The human skin covers an area of average 1.6 m2 in adult. Function of the skin is 
complex. As the largest organ of the human body contribute to the structural and 
functional integrity of it. The human skin takes part in the establishment of endogenous 
homeostasis by protecting the body from exsiccation, controlling the normal body 
temperature, synthesizing of the important molecules and so on. The skin serves as an 
essential barrier to external harmful effects e.g. infections, UV-radiation, mechanical 
injury. In addition to mentioned above the skin functions as the most peripheral 
component of the immune system and initiates a primary immune response to external 
antigens. This primary immune reaction involves the resident cell types o f the skin. This 
network is called Skin Immune System (SIS) consisting of Langerhans cells (antigen- 
presenting cell) which circulate between the skin and lymph nodes, keratinocytes, 
endothelial cells and fibroblasts, which produce a wide diversity of cytokines, 
chemokines and growth factors. Lymphocytes and macrophages extravasate from the 
blood vessels into the skin. These components cooperate with one another to give the best 
response against detrimental stimuli from outside (1,2,3,4,5,6).
The skin has considerable role in the perception of the sensory stimuli that stem 
from outside world. In this process the participant nerve terminals are components of the 
somatosensory system. The nerve terminals in the skin can be grouped on the basis of 
their morphology: free nerve endings (nociceptors) and encapsulated nerve endings (e.g. 
Meissner's corpuscles, Pacinian corpuscles). From point of view of our investigations the 
most interesting nerve terminals belong to a group of the free nerve endings, namely 
polymodal nociceptors, which can reach up as far as the epidermis and can be activated 
by chemical, mechanical stimuli and even heat.
Axons of these polymodal nociceptors make up the majority of very slowly 
conducting, unmyelinated C fibers (7). Up to now more and more experimental data have 
accumulated that the nervous system can modulate various immunological responses, 
including certain inflammatory events in the skin. Neuropeptides released from the 
cutaneous sensory free nerve endings have neurotransmitter and immunoregulatory roles,
they exert mitogenic actions and they can influence the functions of different cell types in 
the skin (8).
Moreover, cells of the skin are able to produce certain neuropeptides, growth 
factors (9,10). Specific receptors and binding sites for neuropeptides have been described 
in different cell types in the skin (kératinocytes, Langerhans cells and fibroblasts) (11).
1.1 Kératinocytes as cellular components o f the skin immune system
Kératinocytes comprise about 90% of the total number of cells found in the 
epidermis. In the past they were highlighted for their production of keratins and lipids, 
which contributed to the structural integrity and barrier formation of the skin. For now it 
is obvious that these cells are active participants of the skin innate immune mechanisms. 
They are able to respond to nonspecific external stimuli with the production o f wide 
range o f inflammatory cytokines, chemokines, growth factors and receptors. O f primary 
inflammatory cytokines they can release interleukin-1 (IL-la, IL-10), interleukin-6 and 
tumor necrosis factoy a  (TNF-a) which can activate certain cellular signaling pathways 
including MAP kinase/JNK signaling system and the nuclear factor-icB (NF-kB) pathway 
that regulates the genes for chemokines, cytokines and even interferons (3,5,12,13,14). 
IL-1 is present in kératinocytes constitutively, but can be upregulated by stimulating with 
lipopolysaccharide (LPS), physical, chemical or thermal injury, ultraviolet irradiation or a 
variety of cytokines and growth factors (i.e. granulocyte/macrophage colony stimulating 
factor (GM-CSF), TNF-a, IL-6, and IL-1 itself) (15).
Kératinocytes have also been identified as source of diverse range of the chemokines 
(both C-X-C chemokines [IL-8] and C-C chemokines) which are o f crucial importance in 
the later phase of inflammation (16).
In addition the kératinocytes can produce and secrete several growth factors such as 
macrophage-colony stimulating factor (M-CSF), granulocyte-colony stimulating factor 
(G-CSF) and GM-CSF to sustain and activate the Langerhans cell population (17). 
Transforming growth factor alpha (TGF-a) and nerve growth factor (NGF) are able to 
influence the proliferation of the various cells types (18).
1.2 Neuropeptides in the skin
To date the presence of more than 20 neuropeptides and neurohormones has been 
verified in human skin by means of immunohistochemistry and radioimmunology 
(19,20,21). O f all the neuropeptides, the tachykinins, and especially the ubiquitous 
substance P (SP), have been best characterized (8,22). SP is involved in neurogenic 
inflammation. Outside the central nervous system, sensory neurons release SP from 
afferent termini directly into the peripheral tissues (23,24), where the neuropeptide can 
initiate numerous inflammatory reactions (25,26). Kératinocytes express specific 
receptors for SP (16), and SP is capable o f upregulating the production of the 
proinflammatory cytokines IL -la  and IL-ip and the chemokine IL-8 in murine and 
human kératinocytes (27). Further, SP is able to upregulate the expression o f the NGF in 
human and murine kératinocytes (28).
SP is often co-localized with calcitonin gene-related peptide (CGRP), a 
neuropeptide present in considerable amount in the skin (29). The most important effects 
of CGRP are its in vivo vasodilatory actions on small and large vessels (30). It can 
enhance endothelial cell and kératinocyte proliferation (31). In addition to regulating the 
vascular function, CGRP can also influence immune responses (11,23,32,33,34).
Vasoactive intestinal polypeptide (VIP) belongs to the family of secretion 
peptides. In the epidermal layer, VIP immunoreactivity is low (35,36). Binding sites for 
VIP have been detected on kératinocytes (31) and immune cells (37). VIP can stimulate 
the proliferation and migration of human kératinocytes, which may play a role in both 
wound healing and hyperproliferation diseases o f the skin, such as psoriasis (38,39,40). 
VIP exerts numerous considerable effects on the action of the immune system 
(41,42,43,44,45,46,47).
1.3 Galanin as a less-known neuropeptid in the skin
Galanin (GAL) is a conserved neuroendocrine peptide, consisting of 29 or 30 (in 
human) amino acids. The peptide was isolated first from the porcine intestine (48). The 
widespread distribution and diverse functions of GAL, together with its highly conserved 
sequence among species, suggest that GAL is an important messenger for inter- and 
intracellular communications. GAL has been found to be widely distributed and 
abundantly expressed in both the central nervous system (CNS) and the peripheral 
tissues, and this has led to studies demonstrating a variety of actions of GAL, including 
neurotransmitter and hormone release, spinal reflexes and nociception (49,50). Peripheral 
effects of GAL have been described both in the autonomic ganglia and in the endocrine- 
gastrointestinal axis, and it participates in the somato-sensory functions, especially pain 
signaling (51,52). Recent evidence suggests that GAL also plays mitogenic and 
neurotrophic roles of importance for the recovery from neuronal injury (53).
In human skin, GAL-like immunoreactivity was first reported in nerve terminals and 
fibers o f the dermis (54). Later, GAL-like immunoreactivity was detected in the follicular 
and interfollicular epidermis and in the ductal cells of the eccrine sweat glands. 
Additionally, GAL-binding sites have been demonstrated around the eccrine sweat glands 
(55) and in the basal zone of the epidermis (56).
1.3.1 Galanin receptors
Biological effects of GAL on different cell types are mediated via three different 
GAL receptor subtypes (GALR1, GALR2 and GALR3) (57,58). The GALRs exhibit high 
interspecies homology and moderate homology to each other. They display a distinct 
tissue distribution. GALR1 is expressed mainly in the CNS (59), GALR2 is expressed in 
considerable amounts both in the CNS and in the peripheral tissues, and GALR3 is 
expressed in noteworthy quantities in the peripheral tissue and in lower amounts in the 
CNS (60,61). The signal transduction mechanisms of the three GALRs are complex. All 
three are able to inhibit adenylate cyclase (62). There is evidence that both GALR1 and 
GALR2 stimulate the MAP kinase in neuronal cells, which may lead to enhanced
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proliferation (63,64). In contrast with GALR1, GALR2, via phospholipase C (PLC), can 
activate protein kinase C (PKC) (65,66) and increase inositol triphosphate (IP3) (63) 
which leads to mobilization of the Ca2+ from the intracellular stores in neuronal cells (67) 
(Fig. 1). The effects of GAL via its GALRs on non-neuronal cells may differ. GAL has 
been reported to be able to inhibit proliferation via GALR1 in oral squamous cell 
carcinoma (68) and via GALR1 and GALR3 in immature rat thymocytes (69). Moreover, 
GAL may play a role in the modulation of cutaneous inflammatory processes (70,71). 
GAL can inhibit cutaneous vasodilatation in the pigeon (72,73). Although GALRs are the 
key to the functional significance of the action of GAL, their expressions in cultured 
human keratinocytes have not yet been investigated. 
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Figure 1. Galanin receptors subtypes and their various signal transduction 
mechanisms (51). 
receptor of 140 kD (TrkA) (89). Whereas the mature NGF is a high-affinity ligand for 
TrkA and low-affinity ligand for p75NTR the proNGF can bind to p75NTR with a higher- 
affinity than mature NGF (90,91) and thus it is an active participant in the initiation of the 
apoptosis mediated by p75NTR. Accordingly, it can play a role in several 
pathophysiological conditions (92,93,94,95).
2. Aims
The aims of the study were:
• to investigate the mRNA and protein expressions of the different GALRs in the 
HaCaT immortalized kératinocyte cell line, in cultured human kératinocytes and 
in normal human skin.
• to verify that GALR2 is a functional receptor by measuring the alteration in 
cytosolic Ca2+ in cultured human kératinocytes under effect o f the GALR2-ligand 
binding.
• to investigate systematically the effects of the neuropeptides SP, CGRP,VIP and 
GAL on the inflammatory mediator production (IL-la, IL-8 and TNF-a) o f the 
kératinocytes.
• to asses the role o f the neuropeptides SP, CGRP,VIP,GAL in the regulation of the 
production of proNGF/NGF and their secretion from cultured human 
kératinocytes.
3. Materials and Methods
3.1 Cell cultures
HaCaT is a spontaneous immortalized non-tumorigenic human keratinocyte- 
derived cell line (kindly provided by Dr N.E. Fusening, Heidelberg, Germany). HaCaT 
cells were cultured in a high-glucose Dulbecco s modified Eagle medium (Gibco BRL, 
Eggstein, Germany) supplemented with 10% fetal bovine serum, L-glutamine, antibiotics 
(penicillin and streptomycin) and an antimycotic (amphotericin B).
Adult epidermal keratinocytes were isolated from breast skin specimens from 
healthy donors (females; age group 20-40 years) undergoing plastic surgery. These skin 
specimens were first washed in an isotonic solution supplemented with antibiotic- 
antimycotic solution (Sigma, St. Louis, Missouri USA). To separate the dermis from the 
epidermis, an overnight incubation in dispase solution (Grade II, Roche Molecular 
Biochemicals) was carried out at 4 °C. The epidermis was then incubated in 0.25% 
trypsin-EDTA (Sigma, St. Louis, Missouri USA) for 20 min at 37 °C. Following 
trypsinization, the cell suspension was filtered through a 100 pm nylon mesh (BD, 
Falcon) and centrifuged at 1000 rpm for 10 min at 4 °C. The cell concentration and the 
percentage of viable cells were determined by means of trypan blue staining, using a 
hemocytometer. The cells were seeded in keratinocyte-serum free medium (Gibco BRL, 
Eggstein, Germany) on 25 cm2 tissue culture plastic flasks. The medium was changed 
every 2 or 3 days. Subconfluent primary cultures were harvested by trypsinization and 
were divided into equal two parts. Both cell types were maintained at 37 °C, with 5% 
CO2 in the humidified atmosphere.
3.2 Neuropeptides treatment o f  the cell cultures
On reaching approximately 80% confluence (after the third passage), the cells
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were treated with different neuropeptides, such as SP, CGRP, VIP and GAL at 10' M for 
30 min. Following incubation in a humidified atmosphere of 5% C 02 at 37 °C, the 
keratinocytes were washed with neuropeptide-free medium and fed with fresh medium. 
For control purposes, cells were handled as mentioned above, but without neuropeptide
induction. Total RNA was isolated 3, 6 12 and 24 h after neuropeptide treatment. Cell 
lysates and keratinocyte culture supernatants were collected 10, 24, 48 and 72 h after 
neuropeptide treatment.
3.3 Reverse transcription (RT) -PC R
Total RNA was isolated from cultures by using the TRIzol reagent method 
(Invitrogen, Carlsbad, USA), carried out as described by the manufacturer. One 
microgram of total RNA was reverse transcribed with the ¡Script cDNA Synthesis Kit 
(BioRad Laboratories, Hercules, CA, USA) according to the manufacturer’s instructions. 
After RT, amplification was carried out with an ¡Cycler machine (iCycler IQ Real Time 
PCR, BioRad Laboratories, Hercules, CA, USA). Specific primers of GALR1 and 
GALR2 are listed in Table 1. For detection of the presence of GALR3 mRNA, Human 
GALR3 TaqMan® Gene Expression Assay (reference number: Hs00358572_ml) 
(Applera Hungary Ltd., Budapest, Hungary) was used. The TaqMan probe was Fam dye- 
labeled. After the amplification, 15 pi o f PCR products was run on 1.5% agarose gel in 
the cases o f GALR1 and GALR2, or on 3% agarose gel for the GALR3 product, stained 
with ethidium bromide, photographed and evaluated with Kodak ID Digital Science 
software (Scientific Imaging Systems, New Haven, CT, USA). For the DNA sequence 
analysis, the PCR products were excised from the agarose gel under ultraviolet light and 
purified by using the DNA Gel Extraction Kit (V-gene Biotechnology Limited, Hangzou, 
China) according to the manufacturer's instructions. The sequence of the purified PCR 
products was then determined by direct DNA sequencing.
gene sequence cone.
GALR1 sense: 5’-GCTCATCTGCTTCTGCTATG-3’ 450 nM
anti-sense: 5’-GCAGCCAGGAGATTCCAA-3’ 450 nM
GALR2 sense: 5’-TTCCTCATCTTCCTCACCATG-3’ 450 nM
anti-sense: 5’-ATGGCACACGGTCAGGTT-3’ 450 nM
Table 1. Primer pairs and primer concentrations used to detect the presence o f GALR1 
and GALR2 subtypes
3.4 Quantitative reverse transcription (RT)-PCR
For quantitative real time RT-PCR, 1 Mg purified total RNA was reverse 
transcribed with the ¡Script cDNA Synthesis Kit (BioRad Laboratories, Hercules, CA, 
USA) according to the manufacturer’s instructions. After RT, amplification reactions 
were carried out with an ¡Cycler machine (¡Cycler IQ Real Time PCR, BioRad 
Laboratories, Hercules, CA, USA). To detect 18S rRNA (as endogenous control), NGF 
and IL-8, we used sequence-specific TaqMan probes. The primers, probes and their 
concentrations are listed in Table 2. The specificities of the IL -la  and TNF-a primers 
were determined by melting curve analysis of the amplicon. For the negative control, we 
omitted the cDNA template and replaced it with water. Each of the PCR reactions was 
carried out in duplicate. The PCR product was detected by measuring the increase in 
fluorescence. The amount of cDNA was calculated on the basis of the threshold cycle 
(CT) value, and was standardized by the amount of housekeeping gene (18S rRNA) by 
means o f the 2'aact method (96):
AACt = (Ct, target '  Ct, 1SS rRNA) - (Or, target - CT, 18S rRNA)(reference)
where “target” means the gene o f interest, and “reference” means the untreated 
keratinocytes. PCR results were expressed as fold increases over the control values.
gene sequence cone.
IL -la sense- 5’-AA TTG TAT GTG ACT GCC CAA G- 3’ 200 nM
- ^ ¡ ¡ ¡ ^ T ^ T A  GTT CTT AGT GCC GTG AGT T - 3’ 200 nM
IL-8 sense- V-CA CAC TGC GCC AAC A-3’ 300 nM
antisense: 5‘-CA TCT TCA CTG ATT CTT GGA T-3’ 300 nM
nrnhe- 5V56-FAM/ CTG GGT GCA GAG GGT TGT GG /3BHQ/-3’ 150 nM
TNF-a sense: 5’-CT CCT TCC TGA TCG TGG C-3’ 300 nM
antisense: 5’-GT TCA GCC ACT GGA GCT-3 300 nM
NGF sense: 5’-AG TGC CGG GAC CCA AAT-3’ 200 nM
antisense: 5’-GA GTT CCA GTG CTT TGA GTG AA-3’ 200 nM
nrobe: 5’ - /56-FAM/ CCG TTG ACA GCG GGT GCC G /3BHQ/-3’ 50 nM
18SrRNA sense: 5’-GG CTA CCA CAT CCA AGG AA-3’ 300 nM
"antisense: 5’-CT GGA ATT ACC GCG GCT-3’ 300 nM
nrobe- 5’-/TexasRed/ TGC TGG CAC CAG ACT TGC CCT C /3BHQ/-3’ 50 nM
Table 2. Primer pairs and primer concentrations used to detect the presence o f IL -la, 
IL-8, TNF-a and NGF mRNAs.
3.5 Immunocytochemistry and immunohistochemistry
Cultured cells were harvested by trypsinization. After centrifugation, the cell 
pellet was resuspended in culture medium, and the cells were counted in a Burker 
chamber. Fifty thousand cells were seeded onto glass slides by cytocentrifuge. The slides 
were fixed in acetone for 6 min. Next, the slides were washed in TRIS-buffered saline 
(TBS, pH 7.2), and nonspecific binding sites were blocked with skimmed milk (5% in 
TBS) for 20 min. After washing in TBS, the slides were incubated in goat polyclonal 
antibody against human GALR2 (K-20) (Santa Cruz Biotechnology, CA, USA) at a 
dilution o f 1:10 overnight at 4 °C. Next day, after extensive washing in TBS, the slides 
were incubated with peroxidase-conjugated anti-goat secondary antibody 
(DakoCytomation, Glostrup, Denmark) at a dilution of 1:200 at room temperature for 30 
min. Finally, peroxidase activity was detected with diaminobenzidine as substrate.
For immunohistochemical investigations, human skin samples were obtained from 
people undergoing plastic surgery. Samples were frozen in order to make sections. After 
fixing in acetone, the immunohistochemical staining procedure was essentially the same 
for the immunocytochemistry described above. In both cases, nuclei were counterstained 
with hematoxylin. For negative controls, the primary antibody was replaced in both cases 
with normal goat IgG. Images were acquired with an RT KE camera and SPOT RT v4.0 
software (Diagnostic Instruments, Livingstone, Scotland) through an Axioplan 
microscope (Opton, Carl Zeiss AG, Oberkochen, Germany).
3.6 Western blotting
Cultured human keratinocytes and human brain tissue (obtained from Department 
o f Pathology) were lysed in 1 ml lysis buffer containing 62.5 mM TRIS (pH 6.8), 5 mM 
EDTA, 1.5% SDS, 5% P-mercaptoethanol and 0.2% proteinase inhibitor (Sigma, St. 
Louis, Missouri USA). Cell lysates were centrifuged for 15 min at 14000g. After 
separation by electrophoresis on 10% SDS-PAGE proteins were transfered to blotting 
membrane (BioRad Laboratories, Hercules, CA, USA), which was then washed in 2% 
skim milk in TBS (pH 7.4) for 1 h. To detect the presence of the GALR2, goat polyclonal 
antibody against human GALR2 (K-20) (Santa Cruz Biotechnology, California, USA)
was used at a dilution of 1:20 whereas to measure the amounts of the proNGF we used 
rabbit polyclonal antibody against human proNGF (Sigma, St.Louis, MO, USA) at a 
dilution o f 1:100, both of them in 2% skim milk in TBS. Next day, the membrane was 
washed in TBS containing 0.5% Tween 20 (TTBS) and incubated with anti-goat IgG- 
conjugated alkaline phosphatase (Sigma, St. Louis, Missouri USA) at a dilution of 
1:3000, anti-rabbit IgG-conjugated alkaline phosphatase (Sigma, St. Louis, MO, USA) at 
a dilution o f 1:3800 for 75 min, respectively. After washing in TTBS and in TBS, the 
alkaline phosphatase activity was detected with 5-bromo-4-chloro-3-indolyl 
phosphate/nitro blue tetrazolium (Sigma, St. Louis, Missouri USA) as substrate.
The specificity of the polyclonal antibody used against GALR2 was verified by 
preabsorbing the antibody with the blocking peptide (Santa Cruz Biotechnology, CA, 
USA) at a dilution of 1:500 for 4 h prior to the immunoblotting.
In case o f  measuring of the amount of the proNGF blots were developed with a 1:100 
dilution of the rabbit polyclonal anti-actin antibody (Sigma, St. Louis, MO, USA) in 
order to check on the equal loading of the total protein in all lanes. Otherwise, the 
conditions were as described in case o f  proNGF.
The results of the Western blotting were filmed with a Kodak DC290 Zoom Digital 
Camera (Scientific Imaging System, New Haven, CT, USA) and the amount o f the 
proNGF were quantitated densitometrically with Kodak ID Digital Science software.
S. 7 ELISA technique
The protein levels of human IL-la, IL-8 and TNF-a in the supernatant o f the 
third-passage epidermal keratinocytes were measured by using commercially available 
Quantikine human immunoassay kits, according to the manufacture’s protocol 
(Quantikine R&D Systems, Minneapolis, MN, USA). To measure the protein level of 
NGF in the supernatant of the human keratinocyte culture, we used a NGF Emax 
ImmunoAssay System (Promega, Madison, WI, USA), following the manufacturer’s 
instruction.
3.8 Measurement o f intracellular [Ca2+]i
After the second passage, cultured human keratinocytes were seeded onto glass 
slides in order for their culturing to continue until a confluence of approximately 90% 
was reached. The glass slides were then washed twice with a modified Hank’s solution 
consisting o f the following components: 127 mM NaCl, 0.33 mM MgS04, 1 mM MgCL, 
1 mM CaCl2, 0.33 mM Na2HP04, 0.44 mM KH2PO4, and 10 mM HEPES. After washing, 
the cells were loaded with Fura-2/AM (Sigma, St. Louis, Missouri USA), a Ca2+-sensitive 
fluorescent dye, at 3.5 pM final concentration, followed by incubation at 37 °C for 45 
min. Finally, the glass slides were subjected to a further two washings in order to 
eliminate the unnecessary dye. Before measurement of the fluorescence, the cells were 
placed into a dish filled with Hank’s solution containing GAL (Sigma, St. Louis, 
Missouri USA) at 10'8 M for 15 s. The fluorescence of the cultured human keratinocytes 
was measured with a Hitachi F-2500 spectrofluorometer. Fluorescence was excited at 340 
and 380 nm and emission was measured at 505 nm. Maximal and minimal fluorescence 
values were obtained following the addition of Triton X-100 (final concentration: 0.1%) 
or EGTA (final concentration: 4 nM), respectively. Data were calculated according to the 
method of Grynkiewiecz, et al (97).
3.9 Statistical analyses
The data were collected from at least three independent experiments. Quantitative 
data are expressed as means ± SD. Statistical significance was determined by using one­
way ANOVA followed by Dunnett’s and Tukey’s post hoc tests (SPSS, Chicago, IL, 
USA). Differences were considered to be statistically significant when p<0.05.
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4. Results 
Chapter I. Keratinocytes can express GALR2 both mRNA and protein 
level 
4.1 Identification of subtypes of GALR mRNAs in HaCaT cells and cultured 
human keratinocytes 
In the first step, the presence of different GALRs was investigated at the level of 
mRNA. GALR1 and GALR2 were detected by using human small intestine as positive 
control and positive control for GALR3 was human brain cDNA. In the case of GALR1, 
an amplified product with the expected molecular weight was detected on use of the 
human small intestine cDNA as template, but when the cDNAs of the HaCaT cells and 
keratinocytes were used, no amplified product with specific molecular weight could be 
demonstrated (Fig. 3A). On investigation of the expression of the GALR2 mRNA, we 
found a sharp band with the expected molecular weight in the gel when either human 
small intestine or cultured keratinocyte cDNAs were applied as templates for the PCR 
reactions (Fig. 3A). The amplified product was retrieved from the bands and subjected to 
DNA sequence analysis. This proved that the HaCaT cells and keratinocytes expressed 
GALR2 at the mRNA level. In the case of GALR3, we detected a weak band for the 
human brain cDNA, corresponding to the expected molecular weight, but neither the 
HaCaT nor the keratinocyte cDNA gave a signal (Fig. 3B). 
SOObp A 500bp g 
,„„ t 300bp 
300bp 
200bp MM m m «MI»^G.1R2 
C H K C H K C H K 
Figure 3. Expression of the mRNA of GALRs in HaCaT cells and cultured human 
keratinocytes. The PCR product o f GALR1 was 143 bp, and that of GALR2 was 222 bp (Fig. 3A). The 
PCR product of GALR3 was 92 bp (Fig. 3B). (C = positive control, H = HaCaT cells, K = human 
keratinocytes) 
21 
4.2 GALR2 protein expression detected by Western blotting in human 
keratinocyte lysates 
We carried out Western blotting assays on cultured human keratinocyte extracts to 
show the presence of the GALR2 protein. The positive control was a human brain protein 
extract. By using both keratinocyte and brain extracts, we succeeded in demonstrating the 
presence of the GALR2 protein with the expected molecular weight, 42 kDa (Fig. 4A). 
We performed Western blotting experiments using the blocking peptide to verify the 
specificity of the goat polyclonal antibody used against human GALR2. In this case, in 
accordance with our expectations, we did not find a signal either for the keratinocyte 
extract or for the human brain extract (Fig. 4B). 
Figure 4. Detection of the presence of GALR2 by Western blotting in protein 
extracts from cultured human keratinocytes and human brain. Fig. 4A shows the 
presence o f GALR2 with the expected molecular weight (42 kDa). Absorption control experiments were 
performed with the blocking peptide o f GALR2 (Fig. 4B). 
4.3 GALR2 is demonstrated by immunocytochemistry in HaCaT cells and 
cultured human keratinocytes 
The presence of the GALR2 protein was next investigated, using a polyclonal 
antibody against human GALR2. Immunocytochemical investigations were carried out 
with cultured HaCaT cells and human keratinocytes. In both cases, we made a negative 
control to enhance the reliability of the experiments. On negative control of the HaCaT 
cells (Fig. 5A), immune staining was not found, whereas with the polyclonal anti-GALR2 
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antibody (Fig. 5B) relatively uniformly distributed strong staining was observed on the 
total surface of the cells. On negative control of the cultured human keratinocytes (Fig. 
5C), there was no specific staining, but a strong specific immune reaction was detected 
on the surface of the keratinocytes when the polyclonal anti-GALR2 antibody was used 
(Fig. 5D). These findings proved the presence of GALR2 on the surface of the human 
keratinocytes. Interestingly, the more differentiated cells appeared to be less intensively 
stained. 
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Figure 5. Immunocytochemical analysis of GALR2 in HaCaT cells and cultured 
human keratinocytes. Negative controls were made for both the HaCaT cells (Fig. 5A) and the 
keratinocytes (Fig. 5C). HaCaT cells (Fig. 5B, the black arrow shows the surface o f a HaCaT cell) and 
cultured normal human keratinocytes (derived from adult female breast skin) (Fig. 5D) were subjected to 
immunocytochemical studies in order to investigate the expression of GALR2 (the black arrow shows the 
surface o f the keratinocyte; the white arrow shows a differentiated cell). Nuclei were counterstained with 
hematoxylin. 
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4.4 In situ expression of GALR2 in human skin 
We carried out immunohistochemical investigations on skin samples from 5 
persons undergoing plastic surgery in order to identify the layer of the human skin in 
which GALR2 is expressed and how intense this expression is. With the anti-GALR2 
antibody, intense staining was demonstrated in the basal layer of the epidermis and 
around blood vessels in the dermis (Fig. 6B and 6C). Interestingly, we also found very 
strong staining in the bulb area of the hair follicles (Fig. 6D). This was in contrast with 
the negative controls, where there was no staining at all (Fig. 6A). 
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Figure 6. Localization of GALR2 by immunohistochemistry in the different layers of 
normal human skin. Figure shows the expression o f GALR2 in normal human skin. A negative 
control was performed with normal goat IgG instead o f primary antibody (Fig. 6A). Fig. 6B shows the 
more intensive coloration of the basal keratinocytes (black arrow) (orange arrow shows vessel endothelial 
cells). Positive blood vessel cells (black arrows) can be seen in Fig. 6C, while Fig. 6 D presents a cross-
section o f a bulb of a hair follicle. Nuclei were counterstained with hematoxylin. Sections thickness: ~ 4 
pm. 
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4.5 An increased level of intracellular Ca2\ [Ca2+]i, was demonstrated in 
GAL-treated keratinocytes 
The effect of GAL on the mobilization of intracellular Ca2+ was investigated in 
cultured human keratinocytes. The glass-cultured cells were placed in Hank's solution 
containing 10"8 M GAL for 15 s. From the beginning of the measurement up to 
approximately 170 s, no change in [Ca2+]j was noted. A fairly sharp increase was then 
recorded, with a peak at approximately 200 s. The value of [Ca2+]i at the peak was 
increased roughly 5-fold as compared with the starting level. [ C a 2 +]i subsequently 
decreased until it reached 1.5 times the initial [Ca 2 r]i (Fig. 7). 
time (sec) 
Figure 7. Effect of GAL on [Ca2+]j in cultured human keratinocytes. The change in 
[ C a 2 ! caused by 10"8 M GAL in cultured human keratinocytes. [Ca2+], was calculated from three 
independent experiments. 
Chapter II. Cutaneous neuropeptides upregulate the production of 
inflammatory cytokines and NGF in human keratinocyte cultures
4.6 Effects o f  SP on the expressions o f the proinflammatory cytokines 
(IL-la, IL-8 and TNF-a) and NGF/proNGF in cultured human keratinocytes
After the induction of subconfluent cultured human keratinocytes with SP (10‘8 
M), a modest, but significant decrease was experienced in the amount of IL -la  mRNA as 
compared with time-matched controls at 3 h after the treatment. Later, the IL -la  mRNA 
levels gradually inreased in the SP-treated cells, but the difference between the SP-treated 
cells and the controls after 24 h was not yet significant (Fig. 8A). Investigation o f the 
supernatants revealed a 0.5-fold decrease at 10 h and then an almost 2-fold increase in the 
IL -la level at both 24 h and 48 h relative to the untreated cell cultures (Fig. 8B). There 
was a significant rise (especially at 6 h: a 6-fold increase) in IL-8 mRNA expression from 
3 h until 24 h after the SP treatment (Fig. 8C). However, this dramatic increase in IL-8 
mRNA expression was not reflected so strongly in the protein content of the supernatants, 
though we did observe a 2-fold rise at 10 h, and then a 1.5-fold rise in the amounts of IL- 
8 at 24 and 48 h (Fig. 8D). SP treatment led to an approximately 2-fold significant 
increase in TNF-a mRNA level from 3 h to 24 h as compared with the untreated samples 
(Fig. 8E), but we failed to demonstrate the presence of TNF-a in the keratinocyte 
supernatants by ELISA assay (data not shown). As concerns the impact of SP on the 
expression of NGF/proNGF, we experienced biphasic kinetics in the level of the 
NGF/proNGF mRNA. There were significant increases in the levels o f NGF/proNGF 
mRNA at 6 h and 24 h after the treatment (Fig. 8F). The relative proNGF protein contents 
o f the SP-treated keratinocyte lysates as compared with time-matched controls were 
evaluated by means o f Western blotting. We found an approximately 1.6-fold increase in 
the level of proNGF as compared with the control from 24 h up to 72 h (Fig. 8G). The 
mature NGF concentrations of the cultured keratinocyte supernatants were also 
significantly increased after SP treatment, the rise being dramatic (10-fold) at 48 h (Fig. 
8H).
26 
c 2 I 14 i 
& 1.6 
a 
: 14 
; 1.2 
d 0.« 
1 °'4 
2 0,2 
3.6 
• control 
• sp 
V 
I« 
| 
I 4 E . 3 
J 
e 2 
I 1 e 
0 
mm 
6h 12h 24h 
time af ter t r ea tment 
24h 48h 
time after treatment 
e e 
* * 
OJL eh 12h 
time after treatment 
24h 48h 72h 
time after t reatment 
•i 0,5 * 
e o 
c 4,5 
I 4 B 3,5 & 
* m 
0) 3 
I » E 2 
Ik 0 1,5 
Z 
1 ' 
a o,5 
e 0 
1 
* 
_JL Mi en i2h 
time af ter t r ea tmen t 
* 
OA 13 
2,5 
» 1,5 
Ik 
(9 2 6 1 
= 0,5 • 
£ 
3h 6h 12h 24h 
time after treatment 
l ü M 
4Jh 
time a f te r t r e a t m e n t 
72h 
J 1 . 
I 
S 10 
«an 
t ime after t reatment 
Figure 8. The effects of SP on the expressions of proinflammatory cytokines and the 
NGF/proNGF system in cultured human keratinocytes. 
Fig. 8A depicts the changes in I L - l a mRNA expression from 3 h to 24 h after SP treatment ( 1 0 8 M). The 
changes in the secreted I L - l a protein concentration are demonstrated in Fig. 8B. Figures 8C and 8D 
present the changes in IL-8 mRNA expression and IL-8 protein secretion from 3 h to 24 h and from 10 h to 
48 h, respectively. For TNF-a, only the changes in the mRNA expression data are presented in Fig. 8E. 
The alterations in the level o f  NGF mRNA expression (Fig. 8F), the proNGF content in the cell extracts 
(Fig. 8G) and the amount o f  mature NGF secreted in the supernatants (Fig. 8H) are also shown. The 
reported data were calculated as the means ±SD o f  the results o f  three independent experiments. *p < 0.05, 
**p < 0.01. (■ = control, □ = SP-treated cells)
4.7 Effects o f CGRP on the production o f the proinflammatory cytokines 
(IL-la, IL-8 and TNF-a) and NGF/proNGF in cultured human keratinocytes
Human keratinocytes were treated with CGRP (10‘8 M) for 30 min. At different 
time points after the treatment, we investigated the mRNA expressions of IL-la, IL-8, 
TNF-a and NGF (proNGF). Additionally, the IL-la, IL-8 and TNF-a levels were 
measured in the cell culture supernatants. Only a weak increase (1.6-fold) was found in 
the IL -la  mRNA expression at 3 h after the treatment (Fig. 9A), but we succeeded in 
demonstrating a 2-fold increase in the amount of secreted IL -la in the supernatant at 24 h 
as compared with the control (Fig. 9B). Considerable, significant increases (8-fold and 
19-fold) were experienced in the amounts of IL-8 mRNA at 3 h and 6 h after induction 
with CGRP (Fig. 9C). The rise in the amount o f IL-8 mRNA appeared in the amount o f 
secreted IL-8 (5-fold increase) at 10 h relative to the untreated controls (Fig. 9D). The 
level of TNF-a mRNA expression was significantly increased at 3 h and 6 h (5-fold and 
3-fold), but then decreased to 2-fold at 24 h (Fig. 9E). We could not detect secreted TNF- 
a at all in the supernatants (data not shown). After CGRP treatment, the NGF/proNGF 
mRNA expression displayed a considerable enhancement at 3 h (7-fold) and 6 h (4-fold) 
after the treatment (Fig. 9F). This was reflected in the proNGF protein contents o f the cell 
lysate at 24 h and 48 h (Fig. 9G), which were increased up to about 1.6-fold, and then 
decreased (0.5-fold) at 72 h as compared with the untreated samples. The level of 
secreted mature NGF production was also increased in the supernatants o f CGRP-treated 
keratinocyte cultures, from 24 h to 72 h (a significant 2-fold rise at 24 h and a 4-fold rise 
at 48 h) (Fig. 9H).
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Figure 9. The effects of CGRP on the expressions of IL- la , IL-8 and TNF-a and the 
NGF/proNGF system in cultured human keratinocytes. 
The changes in I L - l a mRNA expression and secreted I L - l a protein concentration in the CGRP-induced 
human keratinocytes are presented in Figs. 9A and 9B. Figs. 9C and 9D demonstrate the concentrations of 
IL-8 mRNA and secreted IL-8 protein in different time intervals after treatment with CGRP (10"8 M), o f 
cultured human kératinocytes. Fig. 9E shows the changes in content o f  TNF-a mRNA. The changes in 
NGF/proNGF are demonstrated in the following three Figs, which depict the alterations in the level o f  NGF 
mRNA expression (Fig. 9F), the proNGF content in the cell extracts (Fig. 9G) and the amount o f  secreted 
mature NGF in the cell culture supernatants (Fig. 9H). The reported data were calculated as the means ±SD  
o f  the results o f  three independent experiments. *p < 0.05, **p < 0.01. ( .  = control, □ = CGRP-treated 
cells)
4.8 Effects o f VIP on the expressions o f the proinflammatory cytokines 
(IL-la  IL-8 and TNF-a) and NGF/proNGF in cultured human kératinocytes
We analyzed the effects of the VIP on the expressions of the different 
proinflammatory cytokines and the NGF/proNGF system. A 2-fold induction o f IL-lct 
mRNA expression was detected in the VIP-stimulated cultures after 3 h, and there was 
then a 0.3-fold transient decrease in the amount of mRNA at 6 h (Fig. 10A). ELISA assay 
revealed a rise of about 2-fold in the secreted IL -la  protein content in the VIP-stimulated 
cell culture supernatants from 10 h to 48 h as compared with the untreated culture (Fig. 
10B). The IL-8 mRNA expression in VIP-treated cultures exhibited a 4.5-fold increase at 
3 h, after which the amount of IL-8 mRNA fell to 1.7-fold that in the untreated cultures, 
and remained at this level until 24 h (Fig. 10C). To determine whether the expression of 
IL-8 mRNA correlates with the protein expression, we also investigated the IL-8 protein 
expression in the supernatants of the cultured kératinocytes. A 1.6-fold increase in IL-8 
protein level was observed both at 24 and at 48 h after stimulation of the cells with VIP 
(Fig. 10D). There was a decrease of about 0.2-fold in the expression of TNF-a mRNA at 
6 h after VIP treatment, and we then experienced a modest rise (1.7-fold) at 24 h relative 
to the simulated cultures (Fig. 10E). Finally, we examined the impact of VIP on the 
proNGF/NGF expression by the kératinocytes, and the level of NGF/proNGF mRNA was 
found to be increased a 5-fold in the VIP-treated cell cultures at 3 h. This was followed 
by a fall at 6 h, and then a slight rise up to 24 h (Fig. 10F). Western blotting revealed a 
1.5-fold increase in the level of proNGF in the kératinocyte lysates relative to the 
untreated cultures at 48 and 72 h (Fig. 10G). Although the proNGF content o f the 
kératinocytes underwent only a modest change, the level of secreted mature NGF 
exhibited a significant increase at 24 h (3.7-fold) in the supernatants of the VIP-treated 
kératinocytes (Fig. 1 OH).
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Figure 10. The effects of VIP induction on the expressions of proinflammatory 
cytokines (IL-la, IL-8 and TNF-a) and the NGF/proNGF system in cultured human 
keratinocytes Cultured human keratinocytes were treated with VIP at 10"8 M for 30 min. The effects o f 
the treatment on the levels of I L - l a mRNA and I L - l a protein are presented in the Figs. 10A and 10B, and 
the changes in the expression of IL-8 mRNA and the secreted IL-8 protein concentration in Figs. 10C and 
10D, respectively. TNF-a could not be detected by ELISA in the cell culture supernatants, and thus only 
the TNF-a mRNA data are to be seen in Fig. 10E. The alterations in NGF mRNA expression in time are 
shown in Fig. 10F. The proNGF content in the keratinocyte cell extract is demonstrated in Fig. 10G, and 
the mature NGF concentration in the cell culture supernatants in Fig. 10H. The reported data were 
calculated as the means ±SD o f  the results o f  three independent experiments. *p < 0.05, **p < 0.01. (■ = 
control, □ = VIP-treated cells)
4.9 Effects o f GAL on the expressions o f the proinflammatory cytokines 
(IL-la, IL-8 and TNF-a) and NGF/proNGF in cultured human keratinocytes
The effects of GAL on human keratinocytes are not well known. Accordingly, it 
appeared obvious to examine its effects on certain cytokines and the proNGF/NGF 
system expressed by keratinocytes. After induction of the cultures with GAL, we found a 
significant 5-fold increase in the IL -la mRNA expression at 3 h, and there was then a 
fluctuation in the IL -la mRNA level as compared with the untreated cultures (Fig. 11A). 
A significant rise of from 1.5-fold up to 2.1-fold significant rise in the secreted IL-la 
protein level in the supernatant was observed from 10 h up to 72 h (Fig. 1 IB). A more 
dramatic, 17-fold increase was seen in the IL-8 mRNA expression of the GAL-treated 
keratinocyte cultures at 3 h and 6 h after the GAL treatment, and a rise o f about 5-fold 
could be detected even at 12 h (Fig. 11C). The secreted IL-8 protein levels were also 
significantly increased relative to the untreated cell cultures, with a 6.5-fold rise at 10 h 
(Fig. 1 ID). GAL upregulated the TNF-a mRNA expression from 3 h up to 6 h (9.7-fold 
and 3.3-fold) (Fig. HE). TNF-a protein could not be demonstrated by means of ELISA 
assay (data not shown). GAL exerts marked effects on the expression of NGF/proNGF by 
the keratinocytes. An increase of approximately 5-fold was observed in the amount of 
NGF/proNGF mRNA at 3 h after induction with GAL, and we found 3 times as much 
NGF/proNGF mRNA as in the control cultures at 6 h (Fig. 1 IF). Investigation o f the cell 
lysates by Western blotting demonstrated significant 1.4-fold and 2.1-fold increases in 
the proNGF level at 24 h and 48 h, respectively, as compared with the non-induced 
cultures. (Fig. 11G). Interestingly, the level of mature NGF secreted into the GAL-treated 
cell culture supernatants was highest (14-fold) at 72 h (Fig. 11H).
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Figure 11. The effects of GAL on the expressions of proinflammatory cytokines and 
the NGF/proNGF system by cultured human keratinocytes The changes in time o f the IL-
l a mRNA expression in the cultured human keratinocytes after GAL induction (10 s M) are illustrated in 
Fig. 11 A, and the alterations in the secreted I L - l a protein concentration in Fig. 1 IB. The changes in 
expression o f IL-8 mRNA and IL-8 protein are depicted in Figs. 11C and 1 ID, respectively. For TNF-a , 
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only the mRNA data are shown in Fig. HE. The amounts of NGF mRNA after induction o f the 
keratinocyte cells with GAL are presented in Fig. 1 IF. The changes in expression o f the proNGF in the cell 
extract are to be seen in Fig. 11G. The content of mature NGF in the cell culture supernatants are 
demonstrated in Fig. 11H. The reported data were calculated as the means ± S D o f the results o f three 
independent experiments. *p < 0.05, **p < 0.01. ( • = control, • = GAL-treated cells) 
4.10 Cultured human keratinocytes can secrete proNGF 
By using the anti-proNGF antibody, we succeed in detecting the presence of 
proNGF in the supernatants of both the control keratinocytes and the neuropeptide-
treated keratinocytes at 48 h (Fig. 12). With the available Western blot assay, we could 
not distinguish any difference in proNGF secretion between the control keratinocyte 
cultures and the cell cultures treated with different neuropeptides. 
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Figure 12. Detection of the presence of precursor NGF (proNGF) in the 
supernatants of the cultured human keratinocytes. Western blot experiments revealed the 
presence o f an - 75 kDa prohormone (proNGF) in the supernatants o f both the control and the 
neuropeptide-treated cultured human keratinocytes on the use o f polyclonal antibody against proNGF at 48 
h. One representative picture o f three independent Western blots. (C = control cells, GAL = galanin-treated 
cells, VIP = VIP-treated cells, SP = SP-treated cells, CGRP = CGRP-treated cells) 
5. Discussion
5.1 GALR2 is expressed by human kératinocytes both at the level o f mRNA 
and protein
GAL and the GALRs are known to be widely distributed in the central and 
peripheral nervous systems, but only a few data are available on their extraneuronal 
distributions (98,99). The first description of its extraneuronal expression in the skin was 
provided by Ji, et al. (56), who found GAL-binding sites and GAL mRNA expression in 
the epidermis and the dermis of the rat hindpaw. In their inflammation model, the 
epidermal and dermal expressions of GAL mRNA and GAL-binding sites were compared 
in inflamed versus normal rat skin. In the normal epidermis, a few cells labeled weakly 
for GAL mRNA, but inflammation evoked marked increases in GAL mRNA levels in the 
epidermis. In the control dermis a few GAL-positive cells were observed. On 
inflammation, many GAL mRNA-positive cells were seen in the dermis. Double staining 
immunofluorescence experiments indicated that most of the GAL-positive cells in the 
dermis are immunocytes. In normal skin, GAL-binding sites were observed in the basal 
layer of the epidermis. There was no distinct difference in GAL-binding sites between the 
normal and the inflamed epidermis. No GAL-binding sites were demonstrated in the 
normal dermis, whereas the inflammation evoked a strong signal of GAL binding.
The expression of GAL in the epithelium of the rat molar gingiva has been 
reported (10) and the presence of GAL-like immunoreactivity has also been demonstrated 
in human skin (55). The latter study revealed that GAL and the GALRs are expressed in 
neuronal and extraneuronal positions in human skin. Kofler, et al. (55) investigated the 
presence o f GAL-binding sites in the skin by means of [125I]-GALR autoradiography and 
found GAL-binding sites around blood vessels and sweat glands, but they could not 
detect GAL-binding sites on the kératinocytes. In fact, there is a discrepancy between the 
lack of GAL-binding sites in the human skin as reported by Kofler, et al. and our own 
findings. We used a different methodology: we first identified mRNA for GALR2 in 
cultured human kératinocytes and then demonstrated GALR2 protein expression in 
cultured kératinocytes by Western blotting and by immunohistochemistry, using a
polyclonal antibody against human GALR2.
The functions of GAL are mediated by three distinct G-protein-coupled receptors, 
GALR1, GALR2 and GALR3. We investigated the mRNA expressions of all three 
GALR subtypes, using a PCR technique with GALR-specific primer pairs in HaCaT cells 
and cultured human kératinocytes. Human small intestine cDNA was used as control for 
GALR1 and GALR2 (100) and human brain cDNA for GALR3 (61). GALR1 was 
detected only when the small intestine cDNA was used as template; with the kératinocyte 
cDNA, we could not demonstrate any amplified product at the specific molecular weight. 
Interestingly, we detected an amplified product with around twice the molecular weight 
as compared with that found in the case of the human small intestine cDNA. The 
explanation for this might be dimerization of the amplified product, but additional 
investigations are required for a precise explanation. On the basis of the direct sequencing 
of the purified GALR2 PCR products, both the HaCaT cells and the cultured human 
kératinocytes exhibited GALR2 mRNA expression. We could not demonstrate the 
expression of GALR3 mRNA in either HaCaT cells or cultured human kératinocytes.
Besides the detection of GALR2 mRNA expression in HaCaT cells and cultured 
human kératinocytes, we demonstrated the presence of the GALR2 protein in both cell 
types. Both the HaCaT cells and the cultured human kératinocytes displayed specific 
immunohistochemical staining, with greater intensity along the cell surface of the 
kératinocytes. We used commercially available polyclonal antibody against human 
GALR2, directed against a specific sequence of the C-terminal end of the receptor. It has 
been reported (101) that it is difficult “to stain” 7-transmembrane, G-protein-coupled 
receptors because false-positive staining may occur. There are convincing data for the 
specificity of this antibody in the literature (70). Moreover, we have demonstrated the 
presence of GALR2 protein in the human brain and human kératinocyte protein extracts 
by using the same polyclonal antibody on Western blots. By performing absorption 
control experiments with the blocking peptide for the GALR2 antibody, we were able to 
completely block the GALR2-antibody binding in the Western blotting assay.
In our investigations of the biological relevance of the presence of GALR2 on 
kératinocytes, we observed a transient increase in the cytosolic [Ca2+]j during the GAL 
treatment o f cultured human kératinocytes. This phenomenon is be apparently dependent
on GALR2 via the IP3 pathway, where the released Ca2+ may cause the activation of 
protein kinase C, starting the process of differentiation or proliferation of the
kératinocytes (102).
Work with GAL knock-out and transgenic animals have indicated the possible 
trophic and developmental roles of GAL (53). In GAL knock-out mice, a subset of small 
neurons o f dorsal root ganglia with small-diameter, unmyelinated axons (i.e. probably 
nociceptors) are missing and neuroregeneration in these animals is retarded in vivo (103). 
The nerve injury-induced dramatic upregulation of GAL in both the central and the 
peripheral systems is another indicator of the trophic effects of GAL (53,104). After 
axotomy, the GAL mRNA level is dramatically increased in the sensory neurons (105). 
Other microarray studies on sensory ganglia strongly suggest that similar mechanisms
operate in both sensory and autonomic neurons (106).
Cutaneous nerve injury and inflammation give rise to increased GAL production 
in the skin by both neuronal and extraneuronal routes. GAL may stimulate kératinocytes 
via GALR2 and a protein kinase C pathway to produce nerve-regenerating factors, i.e. 
GAL can cause an upregulation of NGF mRNA expression in cultured human
kératinocytes.
5.2 The neuropeptides SP, CGRP, VIP and GAL upregulate the 
inflammatory cytokine expression in cultured human kératinocytes
Kératinocytes, key cellular components as concerns both the homeostasis and 
pathophysiological processes of the skin, secrete a number of cytokines and are 
stimulated by various biological modifiers (i.e. neuropeptides). In our study, cultured 
human kératinocytes were stimulated with neuropeptides, namely SP, CGRP, VIP, GAL. 
Throughout the study we used a constant concentration of stimulating peptide, 10'8 M. 
We took into considerations which have been described for each neuropeptide to occur 
physiologically in the serum: 10'9 M for SP (107), 10'11 M for CGRP (108) and 10’11 M 
for VIP (109). Data could not find concerning GAL serum concentration. We included 
relatively higher concentrations of stimulating peptides since serum concentrations of 
growth factors, hormones and neuropeptides not necessarily reflect the concentrations in 
the direct pericellular microenvironment, which can exceed serum levels. Based on our
unpublished preliminary experiments and other's studies (31,51,110) finally we choosed 
10 * M as the constant concentration of the stimulating peptide. We have demonstrated 
that SP, CGRP, VIP and GAL, which can be present in cutaneous epidermal nerve 
endings, upregulate the expression of the inflammatory cytokine IL -la  mRNA and the 
amount o f secreted IL -la  in cultured human keratinocytes. CGRP, VIP and GAL caused 
a rapid transient increase in IL -la  mRNA expression, observed 3 h after treatment, and 
the concentration of secreted IL -la  protein in CGRP, VIP or GAL neuropeptide-treated 
cultures were 50-60% higher 24 h after the treatment than in their time- matched controls. 
In our study, SP was found to exert late inductive effects on IL -la  mRNA production (at 
24 h) and on IL -la  secretion (at 48 h and 72 h). All of the investigated neuropeptides 
upregulated the IL-8 mRNA expression to a considerable extent way 3 h to 6 h after the 
treatment, but the enhancements in the amounts of secreted IL-8 protein were modest. 
Interestingly, the degree of upregulation of IL -la  mRNA expression was much lower 
than that of IL-8 mRNA, but the amounts of secreted IL -la  and IL-8 displayed a reverse 
pattern. The explanation of this may be that the preformed IL -la  protein in the cells 
contributes to the increase in the amount o f secreted IL -la , while IL-8 must have been 
produced de novo after the neuropeptide stimulus. SP, CGRP and GAL all caused 
significant increases in TNF-a mRNA expression, but no secreted TNF-a could be 
detected in the cell culture supernatants. It is noteworthy that other authors experienced 
similar difficulties with the detection of TNF-a in the supernatants of cultured human 
keratinocytes by the ELISA method (111). TNF-a is initially synthesized as proTNF-a, a 
type II integral membrane protein, and is then cleaved proteolytically by specific 
enzymes (112). Therefore, the preformed TNF-a mRNA is not translated into protein or 
the TNF-a protein production may be stored intracellularly and further 
microenvironmental stimuli are needed for its release. Overall, keratinocytes are capable 
of accepting information from the nervous system via the released neuropeptides. Nerve­
ending injuries or stimuli from the central nervous system can provoke the release of 
neuropeptides, which can then induce the production of IL -la  and the potent chemokine 
IL-8, a key cytokine in the recruitment o f neutrophils. Our experimental findings furnish
further evidence that neuropeptides may play a direct role in the pathogenesis of 
inflammatory dermatoses (113,114).
5.3 Normal human kératinocytes secrete proNGF and the neuropeptides SP, 
CGRP, VIP and GAL can increase both proNGF production and NGF 
secretion in cultured human kératinocytes
In the second part of our study, we examined the proNGF/NGF expression 
produced by cultured human kératinocytes. Alternative splicing of the whole NGF gene 
can produce precursors o f 27 and 35 kDa (115), which are cleaved to produce mature 
NGF (87). ProNGF can be further post-translationally modified by glycosylation, 
forming distinct molecular weight species (116,117,118) Our Western blotting 
experiments demonstrated for the first time that proNGF is the predominant form 
detected in the lysates of cultured human kératinocytes, at molecular weights of 75 and 
50 kDa. At the lower molecular weight, we failed to demonstrate any form of proNGF or 
mature NGF in the cell lysates on using either anti-proNGF or anti-NGF antibody. 
Yardley et al. (117) reported the presence of the 73 kDa NGF prohormone in extracts of 
ovine flank skin, but they failed to reveal the presence of the mature 13 kDa NGF in the 
same extracts. Hasan et al. (119) recently detected the secretion o f proNGF forms into the 
cell culture media by sympathetic neurons. This result is in accordance with those o f our 
Western blot studies, which demonstrated the presence of the 75 kDa proNGF in the 
supernatants of cultured human kératinocytes. We were also able to detect the presence of 
mature NGF in the supernatants of cultured human kératinocytes. As mature NGF was 
not found in the extract of the kératinocytes, but it was present in the supernatants o f the 
kératinocytes, it is possible that the 75 kDa proNGF was secreted by the cells and that 
extracellular proteases can cleave mature NGF (86). Lee et al. (86) further revealed that 
proNGF has a high affinity for the p75NTR receptor and the proNGF -  p75NTR receptor 
interaction can lead to neuronal apoptosis (92). Since both proNGF and mature NGF 
were found in the supernatants of the cells, and the kératinocytes possess both TrkA and 
p75NTR (120), it may be supposed that the balance between cell survival and cell death 
may be determined by the ratio of the secreted proNGF and the formed mature NGF.
On induction of the kératinocyte cultures with the different neuropeptides, the amount of 
NGF was changed distinctly. SP treatment o f the kératinocytes caused significant 
increases in both NGF mRNA production and the amount of secreted NGF. Our results 
are in accordance with the findings of Burbach et al. (28). The effects of CGRP, VIP and 
GAL on proNGF/NGF production have not yet been investigated. We demonstrated that 
all four neuropeptides can increase the NGF mRNA expression, though to different 
extents. In the cell lysate of neuropeptide-treated kératinocytes, only proNGF can be 
detected, in a concentration about 2-fold that in the time-matched controls. Both the 
control cultures and the neuropeptide-treated cultures can secrete proNGF and mature 
NGF, but the neuropeptide-treated cell cultures produce markedly higher (3-7-fold) 
amounts of NGF-like immunoreactive materials. The exact proNGF/NGF ratio in the 
supernatants of cultured human kératinocytes treated with different neuropeptides is not 
known at present. This question necessitates further investigations.
Our results support the important regulatory capacity of the neuropeptides 
released from cutaneous nerves after an injurious stimulus. SP, CGRP, VIP and GAL are 
able to induce an upregulation of inflammatory cytokine (IL -la) and chemokine (IL-8) 
production, and they can influence proNGF/NGF expression and secretion from 
kératinocytes. The concept of the direct influence of cutaneous nerves on the regulation 
o f kératinocyte proNGF/NGF makes a contribution to our understanding of neural effects
on skin health and disease.
6. Summary
Neuropeptides released from the cutaneous sensory nerve endings have 
neurotransmitter and immunoregulatory roles; they exert mitogenic actions and can 
influence the functions of different cell types in the skin. The one of these neuropeptides 
is the galanin, the role of which is less-known in the skin. Galanin (GAL) is a 
biologically active neuropeptide that is widely distributed in the nervous system. GAL 
exerts diverse action via the GAL receptors (GALR1, GALR2 and GALR3), which 
belong in the superfamily of G-protein-coupled transmembrane receptors. Although the 
GALRs are essential for biological functions, the expressions of different GALR 
subtypes in cultured human kératinocytes have not yet been investigated. The aim of our 
study was to investigate the mRNA and protein expressions of the different GALRs in the 
HaCaT immortalized kératinocyte cell line and in cultured human kératinocytes. When 
reverse transcription PCR was used with different GALR-specific primers, only GALR2 
mRNA was identified in cultured HaCaT cells and kératinocytes. Sequencing of the PCR 
products proved the presence of GALR2 mRNA in the kératinocytes. The presence of 
GALR2 protein was next investigated, using a polyclonal antibody against human 
GALR2 Both the HaCaT cells and the cultured kératinocytes displayed specific 
immunohistochemical staining, with higher intensity on the surface of the kératinocytes. 
Immunohistochemical investigations of normal human skin specimens revealed that 
GALR2 was expressed with high intensity in the basal layer of the epidermis and also 
around the hair follicles in the dermis. GAL treatment of the kératinocytes resulted in an 
increase in cytosolic Ca2+ concentration, suggesting that GALR2 is a functional receptor.
The further aims o f our study were a systematic investigation of the effects of the 
neuropeptides substance P (SP), calcitonin gene-related peptide (CGRP), vasoactive 
intestinal polypeptide (VIP) and galanin (GAL) on the inflammatory cytokine production 
(IL -la , IL-8 and TNF-a) of the kératinocytes, and a study of their role in the production 
and secretion o f nerve growth factor (NGF) and its precursor molecule (proNGF). 
Cultures of normal human kératinocytes were treated with 10'8 M SP, CGRP, VIP or 
GAL for 30 min. After different time intervals, cells were harvested for total RNA 
isolation; in addition, cell lysates and supernatants were collected. The effects of the
neuropeptides on the mRNA expressions of the different cytokines and NGF were 
investigated by Q-RT-PCR and the protein levels were studied by means of ELISA 
assays and Western blotting. Each of the four neuropeptides induced increases in the 
expressions of IL -la , 1L-8 and TNF-a mRNA. Increases appeared in the amount of the 
IL -la  protein in the supernatants of neuropeptide-treated cells, and the IL-8 secretion 
was mildly elevated, while secretion of TNF-a remained undetectable. The four 
neuropeptides increased the NGF mRNA expression to different extents. In the cell 
lysates o f the keratinocytes, only proNGF could be detected, its concentration in the 
neuropeptide-treated cells being approximately twice that in the time-matched controls. 
Both control cultures and neuropeptide-treated cultures were found to secrete proNGF 
and mature NGF, but neuropeptide-treated cell cultures produced markedly higher (3-7- 
fold) amounts of NGF-like immunoreactive materials. The results demonstrated that 
neuropeptides released from cutaneous nerves after an injurious stimulus are able to 
induce an upregulation of IL -la  and IL-8 production; they are additionally able to 
influence the expressions of proNGF/NGF and their secretion from the keratinocytes. 
These findings may contribute toward an understanding of the neural influence on skin
health and disease.
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